Decision: Favourable

Study Title:

A 52-week, randomised, double-blind, double-dummy, parallel group, multicentre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophil

  • NREC Code:

    21-NREC-CT-170

  • Decision:

    Favourable

  • Meeting Date:

    12/12/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Desmond Michael Murphy

  • PI Institution:

    Cork University Hospital

  • Sponsor:

    IQVIA on behalf of GlaxoSmithKline Research & Development Limited

Scroll to Top
Skip to content